TNGX
Tango Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.81
P/S
37.78
EV/EBITDA
-21.69
DCF Value
$-13.25
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.3%
Operating Margin
-178.4%
Net Margin
-162.9%
ROE
-50.3%
ROA
-25.5%
ROIC
-29.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-38.7M | $-0.30 |
| FY 2025 | $62.4M | $-101.6M | $-0.87 |
| Q3 2025 | $53.8M | $15.9M | $0.14 |
| Q2 2025 | $3.2M | $-38.9M | $-0.35 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.31
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.